Bioxtreme has secured a new strategic investment led by Serra Holding, a family office focused on healthcare across hospitals, mental health, and medtech. The funding brings Bioxtreme’s total to $15 million, supporting global expansion, strengthening operations in the U.S. and Europe, and advancing the launch of Plaxtreme, a robotic rehabilitation device designed to enhance neuroplasticity and accelerate motor recovery.
Plaxtreme is designed to address the restoration of functional hand movement. Combining precision robotics, immersive virtual environments and Bioxtreme’s proprietary error augmentation technology, Plaxtreme restores grasp and release while accelerating recovery and improving functional outcomes for users. Key capabilities include:
Patented Error Augmentation Technology :
Amplifies movement errors to trigger the brain’s natural adaptive responses, accelerating motor learning and improving movement accuracy.
Personalized Adaptive, AI-Based Learning:
- AI analyzes movement performance in real time, adjusting subtle force demands and therapy parameters.
- Continuously adapts to support progressive learning. Supination and Pronation Training- Supports natural forearm rotation for functional movement.
- Improves coordination for daily tasks. Functional, ADL-based activities in an interactive, 3D environment.
- Gamified tasks drive engagement and high repetition practice
Adaptive Feedback Driven Rehabilitation:
- Real-time, visual feedback supports continuous progress. Automatically adapts difficulty to the patient’s ability.
- Designed for Smooth, OT Workflows – Quick setup with no complex calibration, and seamless left/right and transition. Convenient hand positioning for efficient clinical use
Bioxtreme’s portfolio also includes Dextreme, an advanced robotic rehabilitation system for upper-limb recovery that also applies adaptive error augmentation forces to accelerate motor learning and restore functional independence.
To support the introduction of Plaxtreme and the company’s expansion, Bioxtreme is strengthening its leadership and scientific collaboration across key markets with the additions of:
Eyal Samuel Shachar, Chief Executive Officer – A seasoned executive with experience leading strategy, operations, and growth across scaling global organizations.
Oded Lazarovich, VP Product – An engineering and product leader specializing in robotic medical systems development from concept through commercialization.
Scientific Advisory Board additions include:
James L. Patton, PhD – Supporting U.S. expansion. A Professor of Engineering at the University of Illinois at Chicago and recognized leader in biomechanics and neurorehabilitation research, guiding clinical integration across North America with extensive knowledge in error augmentation in neurorehabilitation robotics.
Franco Molteni, MD – Leading European clinical expansion. Scientific and Clinical Director at Villa Beretta Rehabilitation Research Innovation Institute, with more than four decades of advancing technology-driven rehabilitation.
“Bioxtreme is entering an exciting phase of growth as we expand both our leadership team and our scientific foundation,” said Eyal Samuel Shachar, CEO of Bioxtreme. “With new investment from Serra Holding, the addition of world-class scientific advisors, and the launch of Plaxtreme, we are strengthening our ability to translate cutting-edge neuroscience into rehabilitation solutions where error becomes independence, impacting the lives of patients who need it most. We’re excited for this next step in the company’s growth.”
Leadership expansion across the U.S. and Europe supports global growth of next-generation neurorehabilitation robotics. Learn more here.
Related Posts:
Administrative Bottlenecks Drive Patient Delays in U.S. Healthcare
